prep materi week biotech circu
sf expect confer
question manag team
ahead next week major healthcar confer us biotech seigerman
auster put togeth comprehens list expect compani
cover present also includ comprehens question bank
compani manag find summari expect cover
compani includ like pre-report earn provid guidanc commerci
launch updat pipelin updat and/or program statu updat
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
possibl updateshighlight earli earn guidancecommerci launchupdatessignific pipelin updatesprogram statu charl martineau pm univers toronto januari
tabl content
expect earli januari
expect earli januari
denot compani schedul analyst event week januari
acceleron martin auster littl new info like luspatercept md regulatori review
bthal launch sotatercept pulsar pah next major catalyst think februari
may discuss develop plan outcom posit note companion
trial spectra open label possibl provid insight inform expect pulsar
cmt result expect januari
aimmun evan seigerman expect palforzia approv launch late
januari possibl earlier expect increment detail launch plan well
updat interact payer regul
alexion martin auster expect increment convers pipelin updat
alexion possibl unexpect highlight could see interim data fcrn
antagonist expect guidanc come report februari consist
evan seigerman anticip quieter expect
commentari recent beigen collabor china well updat otezla
integr prior year use highlight upcom pipelin mileston
across portfolio like new cfo peter griffith first major investor event sinc
assum role januari look detail strateg prioriti
apelli tiago fauth pegasu pnh data head-to-head versu soliri expect
earli januari key event stock though expect debat
commerci opportun pnh continu
argenx tiago fauth focu gmg readout increment
detail possibl studi design dose regimen discuss disclosur made
recent patent applic previou note could also see updat pv potenti
ascendi tiago fauth compani like focu regulatori statu
commerci prep transcon hgh data transcon pth expect
evan seigerman expect focu aducanumab look
increment color file timelin interact regul compani
typic use provid updat strategi may get addit color
biomarin martin auster last year compani provid updat guidanc just-
complet fiscal year could repeat need compani may also provid updat
palynziq launch stat may provid granular regard guidanc alreadi
guid profit confirm valrox us file also expect
cyclerion martin auster data sgc stimul design brain
penetr expect may disclos next week
galapago evan seigerman filgotinib look updat commerci
buildout feedback kol payer engag may get increment time detail
earlier pipelin includ proof-of-concept trial initi toledo asset
gilead evan seigerman filgotinib file us expect
compani provid detail commerci plan may get increment time detail
uc top-line readout phase initi ankylos spondyl last year compani
highlight upcom pipelin event set stage new ceo oday start
march year well look detail manag strategi re-acceler
growth particularli bd capit alloc prioriti
evan seigerman neg readout behind us expect
broader strateg updat think new disclosur unlik next
meaning catalyst expect later year
insm martin auster expect bronchiectasi result come
time trial list complet clinicaltri gov mid-decemb preview
detail also compani non-committ may report revenue/launch stat
given compani pre-report data last year model revenu vs
factset consensu arikayc guidanc also possibl expect
model sale vs consensu
mirati evan seigerman expect rel unev mirati last year
compani provid overview confer look increment
detail timelin updat data sitravatinib interim analysi expect
martin auster compani may provid addit detail nhcm
opportun regulatori path forward although expect mani detail may
disclos full nhcm data present academ confer later
neurocrin evan seigerman compani like pre-announc
ingrezza sale data consensu estim investor
weve spoken discuss possibl neurocrin may start give sale guidanc
believ less like due occasion volatil caus season contract
may get detail compani interact regul
vy-aadc program parkinson
obseva martin auster compani may disclos result treatment
pre-term labor result expect believ investor assign limit valu
program
martin auster expect compani may announc aadc
defici gene therapi bla submit expect also expect
compani could provid addit detail aadc defici patient identif effort
meanwhil firefish sma result expect although expect actual
detail disclos academ confer earli februari translarna
dystrophin studi result expect anytim could provid free call option
studi success could support us approv drug expect compani pre-
report earn disclos guidanc done previou year
model revenu consensu
portola tiago fauth expect detail cerdulatinib develop plan
investor current assign limit valu asset along potenti updat
regeneron evan seigerman compani like pre-announc us
eylea sale in-lin consensu forecast provid
financi guidanc prior year includ sanofi commerci expens
reimburs non-gaap unreimburs sg effect tax rate capit
expenditur may get updat emerg novel oncolog portfolio
believ becom increasingli import driver compani
sarepta martin auster compani may pre-report revenu updat
statu gene therapi manufactur build enrol dmd
ultragenyx martin auster cohort data over-the-counter defici gene therapi program
expect year-end could come next coupl week
key read-through updat overal gene therapi platform capabl
ultragenyx sinc dont expect updat meaning chang investor
assess
uniqur martin auster ind treatment huntington diseas
activ first patient could dose anytim may comment updat
statu trial
unit martin auster compani may announc data on-going
increas studi tyvaso ph ild enrol complet week
treatment period data studi dinutuximab small cell lung cancer also
possibl estimate primari endpoint complet per clinicaltri gov less like
vertex evan seigerman compani typic use deliv updat
overal strategi believ incom ceo/curr reshma kewalramani like
outlin vision strateg prioriti next year ahead manag
transit may get increment detail trikafta launch progress
luspatercept refractori md td b-thal
luspatercept approv treatment b-thal novemb
think us launch trajectori luspatercept b-thal mani clinic
target us mani patient seen clinic latest
term payer discuss say access drug time
think rel posit luspatercept rel
agent develop b-thal time approv europ
frame put take eu launch rel us launch
origin expect adcom mid-decemb discuss luspatercept
bla treatment esa refractory/inelig md howev meet
subsequ cancel likelihood need adcom point
level confid approv question anticip fda
character recent interact agenc
frame think md launch rel bthal launch
unmet need patient receiv infus chronic manag low
hgb mention specialist treat md academ
center mani patient specialist manag walk actual
administr drug home clinic character recent
payer discuss expect drug reimburs medicar part part
 walk us md competit landscap includ drug
current use treat diseas agent develop
outlin xlrn/celg agreement respons rel
celgen term agreement outlin go-to-market
commerci strategi md compar go-to-market strategi b-
luspatercept ip posit
provid updat front-lin md studi command non-
transfus depend b-thal beyond studi power command
suggest might explor luspatercept indic walk
broader luspatercept strategi look futur diseas
recent announc top-lin myelofibrosi mf data summar data
think saw greater benefit combin ruxolitinib vs monotherapi
particularli light seen sotatercept mf
mf mention plan move program forward subset patient
mani patient mf fall within target subset think
durat therapi mf rel md walk agent
develop mf outlin potenti differenti drug
rest pipeline/corpor
sotatercept moa differ current avail pah treatment give
confid sotatercept potenti effect agent pah would
sotatercept fit rel crowd pah landscap expect sotatercept
administ home clinic
sotatercept two trial pah walk design two
studi look see studies/what see clinic meaning
support advanc program studi proceed base
pulsar studi wait spectra studi result evalu next
step number earlier approv pah base provid
perspect potenti approv today rang endpoint
may consid potenti pulsar blinded/pbo control studi spectra
open label frequent efficaci measur exercis capac evalu
spectra insight sota efficaci trial
plan top-line result cmt look
see support continu develop program recent discontinu ace-
fshd expect compani similarli decis one
way respect program
recent announc deal fulcrum focus identif new drug
candidates/target pulmonari space think degre
interest pulmonari diseas rel therapeut categori walk
long-term pipelin strategi think intern develop rel
figur catalyst
part cmt pulsar pah result februari refractori md pdufaapril md bthal beyond ntd resultsy spectra pah command md enrol charl martineau pm univers toronto
latest expect rem program palforzia might includ
impact commerci plan
addit detail share interact fda
latest thought price sort interact payer
feedback far
sort financ need ahead palforzia launch
sort spend ramp expect compani move commerci
aimmun term build commerci capabl us launch
potenti ema approv give us color plan
commerci europ area greatest opportun
think potenti launch palforzia europ
asid relat palforzia major mileston expect
provid updat phase clinic trial egg allergi
result would like see trial
pathway registr upcom catalyst
awar
walk us market opportun
plan commerci surround would requir addit
salesforc familiar allergi
success would consid expand ex-u
allergi close relat peanut perhap experi
palforzia may lead explor similar approach
provid detail soliri ultomiri convers ahu sinc fda
approv octob track rel pnh addit
consider may impact convers dynam
data averag durat soliri therapi ahu patient estim
mix chronic/sporad use sens mix patient treat
commun set vs academ center hospit ahu chronic differ
us ex-u market
provid color differ key region ex-u relat
sourcing/purchas drug pnh/ahu exampl region central
could affect pace soliri ultomiri convers ex-u
quickli convert ultomiri trial patient ole eu countri
approv effect fulli bake guidanc
benefits/limit efficacy/safeti perspect target
factor and/or factor pnh think approach
effect use monotherapi all-com pnh popul pnh
thought overal revenu risk competitor target intra-
extravascular hemolysi
achillion acquisit play dynam much price flexibl
pnh add-on therapeut
what statu timelin sc formul ultomiri target
product profil enhanz product discuss learn expect
term inject volum earli data compar target product profil
recap ip posit on-going litig potenti scenario
ipr could impact busi time-frame proceed
litig ultomiri ip chugai see realist rang
gmg discuss ex-u market dynam term territori still intend
seek approv common hurdles/pushback earli day launch
us base current commerci footprint percentag
potenti address patient believ reach think
pace net patient ad go forward consid clinic trial enrol
updat enrol trend expect ultomiri gmg studi
began expect enrol complet expand label
ultomiri gmg much price flexibl ultomiri potenti
allevi concern biosimilar brand competitor across indic
consid like entranc new competitor gmg next year
expect patient flow chang impact number address
patient ultomiris/soliri
nmosd could frame potenti pace adopt launch base
experi gmg key differ uptak dynam
leverag current expertis presenc neuro
see soliri posit nmosd among non-compl moa il-
even rituximab
option al seem substanti well understood pathogenesi
diseas potenti role complement think bar ultomiri
get meaning uptak market
case studi data inform data use soliri al add
support rational success indic beyond preclin human biopsi data
mechanist complement inhibitor target potenti show
differenti efficaci neuro indic like restrict
broadli discuss see two fcrn antagonist asset rel
competit landscap dose regimen frequenc rout
administr studied/develop expect substanti differenti
given competitor class
import sc deliveri target indic what ideal profil
waiha seen potenti fcrn antagonist competitor announc trial
indic would character potenti head-start timelin ultim
see competit evolv indic
gmg expect fcrn asset establish potenti differenti term
efficaci agent move indic key commerci factor
expect drive share uptak class among fcrn asset
investor seem sporad becom singularli focus alxn concentr risk
within complement franchis actual competitor still least year away yr
biosimilar compon see control chang
sentiment complement franchis tail valu convers label expans re-pric
investor surpris in-licens second fcrn antagonist asset shortli
syntimmun acquisit subsequ manufactur delay
part intend field bet approach develop market
reflect evalu process
factor influenc appetit success ultomiri
launch make interest larger transact ad visibl
busi less urgenc cash flow stream increasingli
like sustain high level mani year see rang deal
rel new management team start greater interest appetit
consid aggress stanc bd perhap look transform
opportun instead increment tuck-in deal
import alexion gene therapi platform capabl remain
lt competit leader orphan/rar diseas space
alexion fairli rapidli becom compani substanti presenc area
market look interest place invest huntington parkinson
gate step commenc phase trial
provid detail potenti design registr trial
think oper margin expans follow year
allud higher expenditur revenu base also expect grow
expect see stabl margin trend next coupl year modest margin
regress possible/accept manag
figur catalyst
catalysttimingcompl franchiseultomiri iv formul launch weekli sc pnh ahu data weekli sc pnh ahu potenti iv/sc gmg iv/sc gmg potenti iv/sc nmosd iv/sc nmosd potenti phase hsct-tma trial phase hsct-tma phase hsct-tma potenti phase adapt studi al trial phase adapt studi al al potenti fcrn fcrn waiha trial initiationearli fcrn sc formul trial initiationearli fcrn sc formul gmg trial fcrn gmg fcrn gmg potenti wilson diseas phase enrol wilson diseas phase wilson diseas potenti phase al amyloidosi trial charl martineau pm univers toronto januari
stock struggl announc initi data novemb
perspect drove stock move/what got investor worri
think miss
one main question reloxalias regulatori path met
regul gener result character natur
convers confid approv base urinari oxal
level acceler basi oppos approv base chang kidney stone
burden fda indic particular urinari oxal lower threshold
want see support acceler file
second area focu degre derisk
confid chang urinari oxal level seen first
lead improv kidney stone made chang design
second studi base result first studi
patient develop kidney stone frequent typic kidney
stone biggest predictor develop anoth kidney stone
urinari oxal level factor well think
relationship urinari oxal level kidney stone binari
continuum goal get peopl normal rang order see benefit
reduct even patient normal meaning walk
design trial power trial
strategy/timelin explor drug patient ckd
current balanc sheet posit much runway provid put
rel time data strategi consid
strengthen balanc sheet posit
expect file timelin expect initi label
expect initi label includ detail drug impact kidney stone format
think price drug data accumul clinic
trial think aid price discuss payer
potenti market comp would point instanc thiola reason comp
least term fit within treatment paradigm acknowledg cystinuria much
less common enter hyperoxaluria payer manag access thiola
expect similar restrict drug
expect compliance/discontinu rate drug
base expect
think uptak label potenti includ inform
drug impact kidney stone format
believ slide indic nephrologist urologist us
curiou identifi subset high-prescrib physician sens
mani patient treat doc
look like oxthera oxazym explor hyperoxaluria back
time-frame happen know data studi also know
happen program
figur catalyst alna
catalysttimingfda engag potenti streamlin reloxalias top-line result charl martineau pm univers toronto
given recent announc beigen collabor think
opportun xgeva blincyto kyproli china
could talk regulatori access dynam china
think beigen collabor differ youv
encount chines pharmaceut market
two recent larg bd transactionshow would character capac
help us better understand intern criteria deal
strategi integr otelza compani structur term market
salesforc
hope differ otezla vs celgen asset
commerci perform improv
provid detail repatha launch progress access
challeng improv commerci uptak aimovig
plan acceler aimovig uptak
given even recent posit opinion chmp view opportun
eu
remind us current approv biosimilar us eu progress
launch far
provid color market dynam biosimilar oncolog vs inflamm
speak commerci opportun tezepelumab timelin bla
omecamtiv phase trial heart failur think
timelin potenti launch commerci opportun
differ competitor attribut want
think durabl next data releas
endpoint would like see nsclc
recent start combin trial mek inhibitor
expect initi data trial combin your
explor
beyond key asset novel oncolog pipelin could
data updat year
area would area interest pipelin expans
provid detail addit etokimab atop dermat atla
data disclos given trial etokimab eosinophil asthma
delay provid insight key consider go/no-go
decis trial updat timelin announc decis futur clinic
develop plan etokimab
recap evid support role chronic rhinosinus nasal
polyp crswnp market opportun indic etokimab
posit treatment paradigm
underli rational explor ppp boehring ingelheim
unsuccess trial indic agent much read-through
efficaci bar clinic readout ppp
provid addit detail time gallop gpp
clinical/regulatori updat expect disclos updat
indic role well establish
outlin asset differ antibodi licens celgen also
agonist indic could potenti explor asset
follow atla trial failur provid insight think
clinic pipelin priorit candid provid guidanc
think expens move forward expect oper cash burn/cash
figur catalyst
catalysttimingetokimab addit data updat etokimab clinic crswnp phase ppp phase charl martineau pm univers toronto
despit converg point complement pathway histor
challeng target outlin potenti advantag target part
complement cascad outlin differ mani patient
exposur date safeti profil
ae profil compar inhibit date provid color
infect rate frequent ae
inclusion/exclus criteria compar pnh studi
reliabl data proxi expect pegasu given differ
baselin dose regimen
confirm dose regimen/rout deliveri explor on-going
trial pnh long sc infus
investor expect secondari endpoint pegasu specif
transfus burden reduct what win perspect provid data
broken patient transfus dependent/independ baselin
stand much manufactur capac
potenti launch studi conduct commerci scale materi
assum posit data gate step file pegasu suffici
potenti approv us eu
potenti launch year away discuss go market strategi
thought overal competit landscap pnh potenti
combination/mono therapi factor b/d may impact address popul
ga conduct studi intravitr wamd patient
meaning find data potenti co-dos anti-
gener thought iver bio zimura data read-through
discuss comp potenti registr path strong
correl improv proteinuria events/outcom
provid detail patient discontinu studi
develop plan cad
recap expect lower dose level current
studi clinic publish data lower
achiev
plan reformul develop anoth peptid differ pk/pd profil
may allow prolong dose interv
much read-through posit pegasu readout indic
valid could expect differenti inhibit versu
current cash posit investor think expens go
forward two larg trial on-going potenti addit studi
figur catalyst
pnh top-lin result head-to-head studi jan cad start trialearli ga enrol complet pnh nave enrol complet spring pnh nave datal ga top-lin result charl martineau pm univers toronto
expect uc/cd market evolv oral launch frame
advantag disadvantag etrasimod moa vs jak-inhibitor
etrasimod rel posit versu agent therapeut class ozanimod
see signific read-through etrasimod forthcom ozanimod uc
readout read-through label potenti ozanimod ms
expect competit balanc modul jaki shift
potenti develop selective/restrict jaki may offer cleaner safeti
discuss timelin expect uc cd program youv laid
ambiti clinic trial plan rel small compani explain step your
take meet intern enrol goal pretti competit set conduct
trial anyth avoid delay issu seen enrol
asset target ibd speak aggress develop plan
cd differ develop plan within space expect
updat fda decis support adapt design fda requir
tradit develop plan would impact timelin
preclin and/or clinic evid guid decis advanc etrasimod
phase studi atop derm ad expect efficaci
set rel uc crohn would look efficaci move
program forward note ad also competit arena conduct trial
think develop strategi etrasimod given
previous state possibl applic indic evalu outlin
overal criteria take indic clinic think balanc
new program versu priorit later stage/larg market effort drug
consid potenti price differenti develop decis long-
term ip strategi etrasimod
ibd/ib patient experi pain outlin spectrum sever
olorinab would fit treatment paradigm drug patient
respond current therapi prospect drug util top
current treatment option avail
would regulatori pathway look like olorinab would follow path similar
linzess larg studi popul would enrol
provid color patient characterist degre
patient receiv prior pharmacolog non-pharmacolog pain therapi
enrol similar patient
mechanist character olorinab decreas inflamm
extent compar modal nsaid
beta antagonist gate step file ind still
earli would expect develop asset broadli decompens heart failur
opportun select develop potenti higher price point
shorter time market
figur catalyst
emerg data seem suggest efgartigimod could favor toler
profil rel mab target fcrn much evid suggest
differenti could explain fc region effector function mab sinc
optim minim function
fc fragment proven superior approach defens argenx posit
competitor attempt develop fragment-bas product much protect
expect base patent and/or know-how
exclus deal halozym util enhanz technolog
develop sc product recap sc dose strategi expect product
profil sort bridg studi requir indic
expect actual multi-dos data enhanz formul
efgartigimod volum amen singl inject sort devic
util product
disclos addit detail dosing/pow on-going phase
studi disclos detail baselin characterist patient enrol
gener compar confirm length infus
detail patent applic suggest on-going adapt studi may util iv
treatment cycl instead chronic dose regimen confirm case
would approach fit-in current treatment regimen patient
disclos mani dsmb meet occur
recommend chang protocol
expect competit landscap evolv competit versu
complement inhibitor even fcrn antagonist play
chang mg-adl seem key registr endpoint program gmg
expect efficaci consid efgartigimod competit
cidp provid estim time studi enrol much
detail commit provid enrol progress and/or result open-label
portion trial go/no go decis point
discuss choic primari endpoint iv itp studi much
inform durabl given novelti expect active/pbo arm
give us detail power
second itp trial discuss pk/pd work youv done expect
abl keep patient remiss sc dose
long patient ole dose new find
indic increasingli competit multipl oral agent avail
develop includ btk inhibitor recap realist commerci
opportun class efgartigimod within fcrn class
compani seem reluct develop fcrn antagonist pv
give us thought case commerci posit
expect efgartigimod potenti pv
anti-drug antibodi efgartigimod studi date shown rel high anti-drug
antibodi rate often compar placebo potenti explan
high rate assay limit complic
investor think price across indic given dispar price point
soc indic believ differ formul suffic allow
flexibl well receiv payer
figur catalyst argx
approach potenti commerci launch provid estim
manufactur capac quickli built manufactur process
multi-step device/cartridg compon reason
expect gross margin steady-st
daili growth hormon market fairli fragment formulari access major
driver share what strategi captur formulari access launch expect
transcon hgh treat differ daili payer
what approxim market size us eu japan potenti size
addit market might explor
market research tell rel current price rebat trend
daili growth hormon product insul think transcon hgh might
increment discounts/low price
potenti long-act growth hormon competitor roughli timelin
program partner alreadi strong presenc gh
market product non-inferior daili assum physician treating/dos
titrat normal growth much differenti expect
physician payer perspect across product second competitor expect
ghd data set launch year potenti
transcon hgh approv expect competit dynam play
build pipelin endocrine/rar program mention plan
build commerci infrastructur us select eu market
initi process expect build presenc gain uptak exist gh
provid addit granular stand bla prep
youv discuss past multipl way establish potenti differenti
profil transcon pth trial beyond primari composit endpoint
repres control serum urinari calcium level well reduct calcium
vitamin requir secondari endpoint see studi
recent indic on-going design expect hit stat-sig
outcom howev pbo respons rate natpara fairli limit primari
endpoint even stricter investor expect readout
impact expect enrol natpara experienc patient may
efficaci endpoinst studi reason expect total
sampl size split nave/natpara-experienc subject
caus commerci perform natpara thu far
expect transcon pth potenti overcom pushback
doctor believ patient rel well manag current soc small
minor still experienc symptom entir consist
literatur avail hypoparathyroid caus disconnect
concentr treatment moderate/sever hypopara patient
expect engage/educ commun physician
current manufactur capabl transcon pth use
commerci process product
expect data releas accomplish studi
develop strategi registr
expect possibl dose titrat transcon
set frame differ way see reliabl target level specif
biomark could help inform
trial go conduct commerci material/devic given similar
transcon hgh that case expect timelin establish
commerci process potenti registr studi
beyond preclin evid evid support potenti
continuous/great exposur lead better efficaci without increas safeti
concern potenti skelet deform
oncolog vertic platform
outlin specif develop plan oncolog product
investor expect timelin mono tx data vs combin possibl
partnership vertic
youv partner program sanofi genentech quit time
investor expect statu updat program econom term
meaning asnd investor
figur catalyst asnd
catalysttimingtranscon initi pbo-control pth phase top-lin hgh bla hgh hgh initi japan studi hgh initi adult oncolog vertic first charl martineau pm univers toronto
high low-dos arm perform markedli better engag trial
could discuss patient number carrier statu protocol version
would abl comment breakdown patient symptomat aria-
high low-dos arm perform markedli better engag trial
next step regulatori standpoint
would character commerci opportun us
strategi ensur adequ manufactur capacity/cap
regulatori strategi europ ou market timelin
expect
overal strategi ms franchis address competit
novel agent upcom gener
investor think potenti outcom tecfidera ipr challeng
expect vumer commerci focu new patient
expect spinraza expect growth
posit spinraza light potenti approv risdiplam
area focu develop outsid ad sma
tau next step program psp failur
could discuss busi develop prioriti compani move forward
think balanc busi develop vs use capit
assetdiseasemilestonetimingbiogen catalyststecfideramultipl sclerosismylan ipr decis natalizumab epilepsyphas top data alpha-synuclein parkinson diseasephas top line datal nsr-rpgr xlrpphase datal catalystsrisdiplamsmanda intrathec charl martineau pm univers toronto januari
safeti profil valrox disclos lft
elev trial led amend protocol walk
exactli observ protocol amend made
protocol amend safeti issu flag dsmb sinc
think peak fviii level well data
plan explor see possibl elev peak fviii level mitig non-
statu approv submiss expect
adcom main takeaway would like investor
event expect initi label
walk data updat plan valrox next year
time updat
outlin competit landscap commerci strategi
expect initi run-rat earli adopt would durabl data
affect commerci uptak target popul view recent
disclosur gene therapi price point frame potenti price strategi
think potenti product cost per dose valrox
announc posit top-line result studi character safeti
profil rate hypotens besid growth veloc character
saw term height score proportion qualiti life measur
walk time present result also expect
data infant/toddl studi
plan meet regul next month main
area focu expect give green light file approv
expect potenti get acceler review expect initi label
frame think price vosoritid data see
import support price stanc outlin market opportun
vosoritid age growth plate close percentag case sporad
vs famili approach compar therapi develop
realiz potenti market year ahead competitor
consid develop next-gener agent target sustain elevations/off
potenti less frequent dose
provid updat palynziq launch discontinu ae profil speed
titrat frame expect eu launch
expect initi data pku gene therapi specif data
expect share look see establish go-forward dose curiou
thought homolog recent data updat think program
see product key advantag pku gene therapi
mention day may consid bd specif therapeut modal
indic interest
figur catalyst
catalysttimingbmn pku gt initi pre-submiss meet gt commenc ind enabl studiesearly/mid data updatemid potenti adcommid present result medic regulatori submiss commenc trial dominantli inherit short potenti charl martineau pm univers toronto
preclin data therapeut hypothesi
stock strong late im curiou thought drove
give confid alzheim diseas influenc gingivali
anoth pathogen herp simplex viru attempt awar
other attempt caus alzheim diseas administ high dose
pathogen pathogen explor herp simplex viru etc
biomark tell patient activ gingivali infect brain
studi correl csf apo level gingipain load
report ad patient pg/gingipain brain howev
anoth studi found lower rate pg brain reconcil
differ gingipain locat region associ
ad patholog coloc tau
mention wrote white paper measur pg/gingipain
brain walk techniqu key differ rel
techniqu use group
correl gingipain load diseas sever
broad spectrum antibiot explor ad result
compar broad spectrum antibiot
besid creat ad mice attempt creat ad larg anim
base high oral dose gingivali
walk us safeti patient discontinu
treatment reason partial clinic hold prevent dose
high level higher use trial
arriv dose studi dose compar
previous mention may perform interim analysi
someth plan conduct rang outcom updat
clinic trial screen gingipain load inclusion/exclus criteria
said plan perform subgroup analysi subgroup
analysi plan
potenti approv path character natur
fda convers respect
figur catalyst
provid addit inform scd-saf test
fda sign tell us would posit
reiter plan top-line data readout
pleas explain determin appropri dose level trial
describ new safeti inform contribut enabl expand
current studi scd pt older plan run futur trial
younger pt expand address popul
spoken fda regulatori path forward outlin
would necessari achiev acceler approv pathway recap
commerci strategi asset
sgc amen diseas would consid studi olinciguat
think price strategi much price point
novarti drug weigh decis
updat potenti out-licens praliciguat late stage global
develop commerci agreement made program
altogeth termin
investor expect data asset
expect hear indic target specif
confirm/elabor extent capabl cns-penetr molecul
outsid els expect see top-line readout
walk long-term pipelin strategi
two addit preclin program seriou liver lung diseas
respect updat surround preclin program shed
light potenti indic might target specif
sgc stimul activ produc encourag preclin data variou
diseas fail replic data clinic give convict
compound effect human
stand restructur process follow praliciguat readout
figur catalyst
top-line result healthi volunt earli top-line result charl martineau pm univers toronto januari
pdufa date ba ba ezetimib combo pill expect approv
decis made togeth degre confid approv
provid updat latest fda interact area
focu provid overview efficaci safeti bemedpo acid
fda request adcom thu far process
chanc could chang last minut
much safeti data fda indic would like see number patient length
follow-up fix dose combin pill prior approv much safeti data
expect time
walk efficaci safeti profil ba lt safeti studi
death imbal unrel treatment ba arm give confid
outcom spuriou outlin saw safeti perspect term
ae sae rate discontinu rate rate lft
trial compar approv ldl-c lower agent
outlin saw term reduct trial
hypothesi mechanist perspect see benefit see
weight gain edema import part commerci stori think
lack worsen critic take-away clinician
file approv base ldl-c improv current run
long-term outcom studi briefli walk design trial give
confid ldl-c reduct hscrp improv translat
clinic success cvot studi expect time result cvot
studi way tri reduc risk studi well valid
hscrp biomark
novarti recent announc acquisit mdco read-through see
news see competit landscap play ba
one market segment target patient statin intoler
character statin intoler mean mani patient us meet
outlin plan differenti therapi therapi
market develop expect out-of-pocket cost
bempedo acid compar uptak rate
sinc compani announc lower price
think launch trajectori see amarin launch good
comp think cvot impact ba commerci trajectori and/or pharma
interest asset
provid updat sg infrastructur step take
prepar commerci launch quickli could launch follow approv
expect payer access time launch understand provid
guidanc ahead approv gener comfort current
consensu sale receiv approv
speak current balanc sheet posit expect runway
term eu partnership plan partner japan region
walk long-term pipelin strategi statu ba sustain
figur catalyst
could talk potenti competit product activ acinetobact could
util on/off-label type infect durlobactam target
choos current develop pathway durlobactam instead
typic cuti/ciai indic work expand
trial execut expect see contribut zai lab
expect diagnost tool help identifi patients/spe enrol
think commerci opportun durlobactam establish
type commerci infrastructur believ necessari target
hospitals/cent high rate carbapenem-resist acinetobact
reiter plan top-lin readout attack trial
provid updat enrol pt follow initi
trial septemb still guid readout
expect addit work on-going
updat regard timelin guidanc
signific benefit combin therapi previous state
initi nbp program candid select updat guidanc
regard initi candid select occur
thought likelihood/prospect consolid antibiot space
high probabl near-term initi may improv reimburs offer
incent brand product anti-infect sector
current cash posit addit expect runway
figur catalyst ettx
outlin commerci opportun md popul size
address popul unfit chemotherapi transplant receiv
estim us md patient activ therapi
would higher risk patient opportun increas higher risk md
treat patient us
futur plan studi magrolimab lower risk md popul would
gate step relev cours studi conduct trial less sever
clinic practic limit ae profil specif neutropenia/thrombocytopenia
venetoclax aza util md patient
think bar acceler approv higher risk md cr durat
respons
aml patient expect mutat benchmark
respons rate soc patient set
mechanist reason magrolimab aza would efficaci
patient rel broader popul
data frequenc mutant variant allel azacitidin monotherapi
compar data produc far
data analyz t-cell infiltr aza monotherapi investor interpret
data produc aza magrolimab combo
upcom registr trial dlbcl expect popul similar
articul regulatori path forward provid detail
potenti bar fda warrant acceler approv highlight specif
threshold respons orr cr specif point time analysi
treatment landscap clinic pipelin dlbcl evolv frame
think could potenti fit treatment paradigm consid class
adc develop r/r popul size potenti
compare/contrast bar success potenti commerci opportun
indol lymphoma consid differ soc clinic pipelin
landscap evolv past year compani
depriorit program other enter clinic outlin see
posit across field see key differenti featur
give us sens data expect upcom ovarian
colorect cancer trial respons rate would consid compel enough
advanc program preliminari discuss fda regard
first-in-human studi would consid compel
expect adjust combin magrolimab ensur enough deplet also
clearanc transplant materi
commerci opportun provid
estim price anyth relat potenti revenu stream
figur catalyst ftsv
first-in-human random md cetuximab safeti ph avelumab phase aza expand efficaci updat durabl rituximab gem/ox phase atezolizumab phase atezolizumab phase rituximab acalabrutinib phase rituximab interim bla file acceler charl martineau pm univers toronto
would talk advantag filgotinib select translat
timelin filgotinib ra indic
walk us thought potenti class label thrombosi
would talk commerci strategi posit compet
see opportun filgotinib sjgren lupu
ipf
would walk us stand franchis ipf
develop standpoint next step
type commerci opportun see ipf franchis
overal strategi behind toledo program given broad indic
announc event
expect disclos target/ later-stag clinic plan program
could detail time key upcom catalyst toledo
talk us scientif rational differ program target
expect addit data toledo target
talk opportun osteoarthr oa
time oa franchis
high-level perspect expect cours
gilead top strateg prioriti
plan acceler earn revenu growth
bd perspect compani favor larger transform deal partnership
deal weve seen galapago go forward
area interest bd therapeut otherwis
would character gilead capac bd
think extern bd vs mean capit alloc
given acquisit otezla see gilead pursu similar effort acquir
market drug right condit premium provid immedi revenu
would compani prefer acquir late-stag asset still clinic trial
launch descovi prep progress could pleas describ
posit descovi vs truvada prep
go forward anticip switch strategi transit patient descovi
would mainli patient higher risk symptomat bone kidney issu
anticip payer may requir patient low risk bone kidney issu
start truvada prep reserv descovi patient signific
plan pursu label expans descovi prep cis-women
would character opportun
current strategi solid tumor indic see
import hurdl still need overcom improv commerci
yescarta think gilead could improv uptak think
futur car-t
give confid autotaxin inhibit ipf correct
target given limit clinic data
expect updat toledo program potenti target select
anticip leader galapago deal give
given failur seen nash view nash franchis signific
opportun still think prudent shift resourc area
assetindicationmilestonetimingfilgotinibucphas data spondylitisiniti phase phase tumor mage trial enrol complet tumor complet enrol phase clinic studi allogen enrol phase data phase top-line arthritisema arthritisfda data gen data gen charl martineau pm univers toronto
given recent failur gvhd next step
believ like meet clinic endpoint
give confid itacitinib succeed chronic
gvhd mechanist make itacitinib suitabl treat patient
acut gvhd
franchis key catalyst next year could reduc relianc jakafi
could talk opportun see jakafi gvhd progress
payor recept cover jakafi gvhd
besid expand chronic indic type benefit could reach trial
add jakafi label gvhd
think posit jakafi gvhd given clear
consensu treatment
increment commerci opportun could expand label chronic
busi develop previous express interest dealshow
think capac transact
type compani interest
much capac transact
feel dermatolog franchis fit within tradit focu
walk us plan commerci topic ruxolitinib ad
vitiligo plan focu primari care physician dermatologist would
requir new sale forc would abl leverag exist rep
type opportun see pemigatinib see think fit
commerci landscap regard competit balversa
differenti pemigatinib light balversa
tumor agnost approach way effect compet space
type opportun see parsaclisib given challeng seen
biolog differ parsaclisib b-cell malign nhl fl mzl
mcl vs dlbcl could potenti drive better result
outlin refractori ntm patient portion
see address perspect annual incid
refractori diseas think revenu curv post treat
initi preval popul physician gener adher label
see term durat therapi discontinu rate sens
durat therapi non-respond month discontinu treatment
month stay therapi past point time new ntm
one area investor focu arikayc reimburs outlin mani
patient cover medicare/medicaid process get formulari
base launch date significantli payer manag arikayc use
averag patient out-of-pocket cost patient assist program
percentag patient cover insur plan arikayc
formulari think gross-to-net adjust today
expect chang next year
outlin arikayc safeti profil sinc launch compar
seen clinic trial expect
outlin number new start past coupl quarter see
stabil new start expect number new start increas
part earn next year plan continu updat street
metric provid histor metric focu
inform allow understand percentag non-convert
continu therapi beyond month
statu time potenti eu jpn approv atu price
franc expect price arikayc europ approv
histor comp eu price jpn price pah
advanc copd ipf cf
provid detail design valid process
design confirmatori studi expect start
valid prior commenc confirmatori studi frame market
opportun confirmatori front-lin studi could unlock trial success
outlin think sg cost initi front-
line studi build intern sale forc outlin current
commerci capabl term size sale forc ex-u plan
ad rep ahead launch region expect cog rate
much could improv time
balanc desir achiev profit versu maxim opportun
arikayc particularli ex-u build pipelin consid strateg
partnership ex-u perspect intern develop vs select
bd healthi sg infrastructur built import leverag
result look see support continu
improv clinic meaning degre confid
figur catalyst
ncfbe result januari japan regulatori eu establish endpoint confirmatori charl martineau pm univers toronto
outlin observ preclin studi efficaci
perspect well valid ttr knockdown relat function benefit
degre ttr knockdown clinic meaning mani month follow-up
much variabl respons see safeti signal
provid updat statu toxicolog studi reiter guidanc
ind submiss
may complet final outlin think
design initi studi patient popul endpoint etc plan dose
patient first cohort dose expect efficaci would intent
administ dose therapeut window quickli expect could see
benefit therapi think disclosur result disclos
